Mirum Pharmaceuticals, Inc. (MIRM)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 127,785 | 111,585 | 90,377 | 77,875 |
| Selling, general and administrative | 63,286 | 57,706 | 50,545 | 49,208 |
| Research and development | 46,067 | 46,044 | 31,710 | 32,672 |
| Cost of sales | 23,421 | 23,018 | 20,806 | 20,227 |
| Total operating expenses | 132,774 | 126,768 | 103,061 | 102,107 |
| Loss from operations | -4,989 | -15,183 | -12,684 | -24,232 |
| Interest income | 3,033 | 3,023 | 3,469 | 3,486 |
| Interest expense | 3,589 | 3,596 | 3,586 | 3,569 |
| Other income, net | 86 | 2,108 | -1,087 | 312 |
| Net loss before provision for income taxes | -5,459 | -13,648 | -13,888 | -24,003 |
| Provision for income taxes | 402 | 1,029 | 347 | 635 |
| Net loss | -5,861 | -14,677 | -14,235 | -24,638 |
| Net loss per share, basic (in dollars per share) | -0.12 | -0.3 | -0.3 | -0.52 |
| Net loss per share, diluted (in dollars per share) | -0.12 | -0.3 | -0.3 | -0.52 |
| Weighted-average shares of common stock outstanding, basic (in shares) | 49,726,823 | 48,889,058 | 47,782,619 | 47,235,080 |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 49,726,823 | 48,889,058 | 47,782,619 | 47,235,080 |